Prior authorization for CGRP preventives is bureaucratic but beatable. Here's exactly what insurers require, what a renewal packet needs, and how to prepare.
Getting approved for a CGRP preventive medication is one hurdle. Staying approved is another. Prior authorization for CGRP monoclonal antibodies requires upfront documentation, and the annual renewal process requires you to prove, with real numbers, that the medication is working. Understanding what insurers actually look for makes the difference between a smooth continuation and a frustrating denial that interrupts treatment.
Prior authorization (PA) is a formal approval process insurers use before agreeing to cover a medication. For most generic preventives, such as beta-blockers, tricyclics, and certain anticonvulsants, PA either isn't required or is minimal. CGRP monoclonal antibodies are a different category entirely. They are brand-name biologics with monthly costs that can reach several thousand dollars without coverage. Insurers treat this price point seriously.
The stated rationale for CGRP prior authorization is clinical appropriateness: the insurer wants confirmation that the patient has a legitimate diagnosis of migraine, that they've already tried and failed less expensive first-line preventive treatments, and that the specific CGRP medication requested is medically necessary. Whether or not you agree with the gatekeeping logic, those are the three things every initial PA is trying to establish.
Most initial PA requests for CGRP preventives require the following:
Diagnosis confirmation. Your neurologist or prescribing physician needs to document a formal migraine diagnosis, episodic or chronic, and specify monthly migraine day (MMD) frequency. The clinical threshold for chronic migraine is 15 or more headache days per month, with at least eight meeting migraine criteria. For episodic migraine with high frequency (typically 4 to 14 MMDs), documentation must establish that the burden is significant enough to warrant preventive treatment.
Step therapy: evidence of prior treatment failure. Almost every commercial health plan and most Medicaid programs require proof that you tried and failed at least two or three older preventive medications before they'll cover a CGRP inhibitor. "Failed" typically means either inadequate efficacy (the medication didn't reduce migraine frequency sufficiently) or intolerable side effects that led to discontinuation. Your prescriber needs to document the specific medications tried, the doses, the duration of the trial, and the documented reason for failure. Vague notes like "tried topiramate, didn't work" are weaker than specifics: "topiramate 100mg daily x 3 months, discontinued due to cognitive side effects and less than 25% reduction in MMD."
Baseline migraine frequency. You need a documented starting point. This is ideally a headache diary or migraine log from the 1 to 3 months prior to starting the CGRP medication, recording how many migraine days per month you experienced. If you don't have this data going in, your neurologist may estimate from clinical visit notes, but actual patient-recorded data is far stronger.
The renewal PA, required annually by most plans, is where thorough ongoing tracking pays off. Insurers are no longer asking whether you should start this medication. They're asking whether it's still working well enough to continue justifying the cost.
The core of any renewal packet is a before-and-after comparison of monthly migraine days. Your prescriber needs to show the number of MMDs before starting the medication and the current MMD count. From there, the packet typically needs to address:
| Document / Data Point | What It Shows |
|---|---|
| Pre-treatment MMD count (baseline) | Starting disease burden before CGRP therapy |
| Current MMD count (past 3 months) | Present disease burden on treatment |
| % reduction in monthly migraine days | Quantified treatment response |
| Acute medication usage days (baseline vs. current) | Reduction in rescue medication dependence |
| MIDAS or HIT-6 score (baseline vs. current) | Functional and disability improvement |
| Pharmacy fill history | Adherence to prescribed regimen |
| Physician attestation of continued medical necessity | Clinical justification for ongoing treatment |
| Documentation of active migraine diagnosis | Confirms ongoing indication |
The neurologist's office assembles the actual paperwork, but the underlying data has to come from somewhere, and that somewhere is largely you.
Practices that see dozens of patients a week are not tracking your migraine days between appointments. When renewal time comes, many offices will ask you to reconstruct your migraine frequency from memory or estimate based on clinic visit notes. That produces vague numbers, and vague numbers produce weak renewals.
A patient who comes to a pre-renewal appointment with three months of documented migraine log data, including specific dates, duration, severity, and acute medication taken, gives their prescriber the raw material to write a detailed, defensible renewal. The same goes for the baseline. If you started a CGRP medication six or twelve months ago, and you tracked your migraine days before starting, that data is now your strongest evidence of response.
Insurance requirements for CGRP prior authorization and renewal vary significantly by plan, state, and specific medication. The information here reflects general patterns across commercial insurance and is intended as orientation, not legal or medical advice. Always confirm your plan's specific requirements with your insurer and work directly with your prescribing physician's office on PA submissions.
The most preventable denial reason is documentation that's too vague to demonstrate benefit. A renewal that says "patient reports improvement" without quantified MMD data gives the insurer almost nothing to approve. Specific pitfalls include:
A denial is not final. Every insurer is required to provide an appeals process, and CGRP PA denials have a meaningful success rate on appeal when the appeal is properly documented.
First-level appeal. Your prescriber submits a formal appeal letter with more detailed clinical documentation. This is where adding specificity matters most: actual MMD counts, disability scores, and a narrative explaining why the medication is medically necessary.
Peer-to-peer review. Your prescriber can request a direct physician-to-physician call with the insurer's medical reviewer. These calls frequently result in approval, especially when the prescribing neurologist can speak to the patient's full clinical picture. Ask your prescriber's office specifically for a peer-to-peer.
Exception requests. If you're caught in a step therapy requirement for a medication you've already tried through a different insurer or years earlier, many states have step therapy exception laws that allow you to bypass repeat trials with adequate documentation. Your prescriber and sometimes your state's insurance commissioner office can help navigate this.
External appeal. If internal appeals fail, most states allow an independent external review by a third-party organization. This is worth pursuing if the clinical case is strong.
The difference between a smooth CGRP renewal and a stressful scramble usually comes down to whether you have data. Monthly migraine day counts, acute medication usage, and notes on severity are the exact numbers that go into a renewal packet. Building the habit of tracking throughout the year means that when your prescriber's office calls to start the renewal process, you're walking in with a complete, organized record rather than trying to reconstruct twelve months of headaches from memory. The paperwork is still the paperwork. But the data behind it can be ready.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
CGRP monoclonal antibodies are expensive brand-name biologics. Insurers use prior authorization to confirm the diagnosis is appropriate, that older cheaper treatments were tried first, and that the medication is producing measurable benefit.
CGRP treatment costs are among the highest in migraine care. This plain-language guide explains why, how insurance works, and how documentation protects your access.
Consistent migraine tracking protects your CGRP coverage, prevents costly denials, and cuts wasted appointments. Here is how documentation saves real money.
Chronic migraine is defined as ≥15 headache days per month. That number determines your diagnosis, your treatment options, and what your insurer will cover.
